美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

GSK plc ADRhedged

70.64

+0.84791.21%

盤後：70.55-0.0864-0.12%16:10 EDT

成交量：111

成交額：7,823

市值：70.64萬

市盈率：- -

高：70.64

開：70.55

低：70.55

收：69.79

52周最高：85.03

52周最低：55.75

股本：1.00萬

流通股本：1.00萬

量比：0.32

換手率：1.11%

股息：2.08

股息率：2.94%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

葛蘭素史克（GSK）擬斥資7.5億美元收購Chimagen旗下TCE項目全球獨家權益

118款生物藥專利懸崖將至，中國藥企業迎戰MNC最大專利懸崖

乙肝新藥中國數據出爐，但實現患者的「治癒夢」仍有門檻

每日经济新闻

功能性治癒率最高61%！乙肝新藥中國數據出爐但7500萬患者的「治癒夢」仍有門檻

每日经济新闻

總額可達12.95億美元！和黃全球首創偶聯藥物出海

和黃醫藥午後飆升逾16%，與葛蘭素史克達成最高12.95億美元腫瘤藥授權合作

老虎资讯综合

藥聞 | 英硅智能上市後首份半年報扭虧創新藥研發加速擁抱AI

聯環藥業上半年扭虧為盈集採續採與創新藥研發協同推進

能夠治癒乙肝的新藥來了？專家：距離攻克乙肝仍有差距，但臨床多了一件新武器

每日经济新闻

葛蘭素史克(GSK)擬發行至少20億歐元債券，以償還併購融資貸款。

博濟醫藥2026年半年報：創新藥研發需求復甦，在手訂單充足，經營現金流明顯下滑

GSK：NUCALA獲加拿大藥品管理局積極報銷推薦，用於成人慢性阻塞性肺疾病治療。

中外製藥與葛蘭素史克簽署抗登革熱病毒抗體「AID351」獨家許可協議

中外製藥與葛蘭素史克達成協議，共同推進登革熱抗體藥物開發

中國銀河證券：實驗動物為創新藥研發剛需小鼠+猴雙主線高景氣

葛蘭素史克：董事會批准根據公司淨資產，按資產市場價值分配公司合併後股本。

百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務不涉及創新藥研發

百花醫藥(600721.SH)：不涉及創新藥研發

百花醫藥(600721.SH)：不涉及創新藥研發

東方證券：AI重構創新藥研發底座國內相關產業鏈公司亦有望受益

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/GSKH/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"GSKH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","market":"US","secType":"STK","nameCN":"GSK plc ADRhedged","latestPrice":70.6364,"timestamp":1789588800000,"preClose":69.7885,"halted":0,"volume":111,"hourTrading":{"tag":"盘后","latestPrice":70.55,"preClose":70.6364,"latestTime":"16:10 EDT","volume":6,"amount":423.8184,"timestamp":1789589404176,"change":-0.0864,"changeRate":-0.001223,"amplitude":0},"delay":0,"changeRate":0.012149566189271809,"floatShares":10001,"shares":10001,"eps":0,"marketStatus":"未開盤","change":0.8479,"latestTime":"09-16 16:00:00 EDT","open":70.55,"high":70.6364,"low":70.55,"amount":7823,"amplitude":0.001238,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789632000000},"marketStatusCode":0,"adr":0,"exchange":"ARCA","adjPreClose":69.7885,"nav":69.73341,"aum":697403.83341,"dividendRate":0.029448,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":70.55,"preClose":70.6364,"latestTime":"16:10 EDT","volume":6,"amount":423.8184,"timestamp":1789589404176,"change":-0.0864,"changeRate":-0.001223,"amplitude":0},"volumeRatio":0.321367,"impliedVol":0.3521,"impliedVolPercentile":0.9741},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","floatShares":10001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.321367,"shares":10001,"dividePrice":2.0801,"high":70.6364,"amplitude":0.001238,"preClose":69.7885,"low":70.55,"week52Low":55.7526,"pbRate":"--","week52High":85.03,"institutionHeld":0,"latestPrice":70.6364,"eps":0,"divideRate":0.029448,"volume":111,"delay":0,"ttmEps":0,"open":70.55,"prevYearClose":68.2031,"prevWeekClose":66.9705,"prevMonthClose":69.8569,"prevQuarterClose":73.8574,"fiveDayClose":67.6331,"twentyDayClose":71.1955,"sixtyDayClose":71.6072},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GSKH\",params:#limit:5,,,undefined,":[{"date":"2026-06-16","symbol":"GSKH","amount":0.92785,"announcedDate":"2026-06-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-16","defaultRemindTime":1781616600000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-23","payableDate":"2026-06-16","currency":"USD","dateTimestamp":1781582400000,"payDate":"2026-06-23"},{"date":"2026-03-16","symbol":"GSKH","amount":0.36332,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"GSKH","amount":0.78682,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GSKH\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.78682,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.36332,"currency":"USD"},{"executeDate":"2026-06-16","recordDate":"2026-06-16","paymentDate":"2026-06-23","value":0.92785,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GSKH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GSKH\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667637649","title":"葛蘭素史克（GSK）擬斥資7.5億美元收購Chimagen旗下TCE項目全球獨家權益","url":"https://stock-news.laohu8.com/highlight/detail?id=2667637649","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667637649?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 18:32","pubTimestamp":1789468371,"startTime":"0","endTime":"0","summary":"金吾财讯 | 葛兰素史克（GSK）已与Chimagen Biosciences达成协议，将以高达7.5亿美元的交易总额，收购后者一款用于治疗多发性骨髓瘤的三特异性T细胞衔接器（TCE）项目的全球独家权益。根据协议，GSK将向Chimagen支付一笔首付款，并根据后续研发与商业化进展支付相应的里程碑付款。该候选药物能够同时靶向T细胞及两种肿瘤相关抗原，目前预计将于2027年正式进入I期临床试验阶段。此前，双方已就另一款处于I期临床、针对CD19/CD20的双重TCE药物CMG1A46达成合作，本次交易标志着GSK在多发性骨髓瘤及血液瘤产品线上的进一步深化布局。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306052","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4585","BK4007","GSK.UK","GSK","GSKH","BK4588","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666563124","title":"118款生物藥專利懸崖將至，中國藥企業迎戰MNC最大專利懸崖","url":"https://stock-news.laohu8.com/highlight/detail?id=2666563124","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666563124?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 15:26","pubTimestamp":1789025185,"startTime":"0","endTime":"0","summary":"BCG合伙人杜菁博士指出，未来几年全球MNC将迎来史上最大专利悬崖，有118种生物制剂将会失去相应的专利保护，涉及2340亿美元市场。然而，目前这118款即将到期分子中，只有极少数在火热开发，大量缺口有待生物类似药填补。目前来说，创新药出海还没办法完成这个闭环，但生物类似药作为先头部队做出海试验，企业风险和获益会更高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789025064363150858","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["FXH","PBPH","PJP","IHE","TMED","TRUH","BBP","159839","RSPH","MEDI","APXH","BME","JDOC","IYH","BBH","PPH","GSKH","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665937331","title":"乙肝新藥中國數據出爐，但實現患者的「治癒夢」仍有門檻","url":"https://stock-news.laohu8.com/highlight/detail?id=2665937331","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665937331?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:51","pubTimestamp":1788871868,"startTime":"0","endTime":"0","summary":"中国慢性乙型肝炎（以下简称慢乙肝）患者的“治愈”故事，正在萌芽。日前，在新加坡召开的亚洲肝病学峰会暨乙肝病毒治愈科学会议上，反义寡核苷酸（ASO）药物Bepirovirsen全球Ⅲ期研究（BWell研究）的中国人群数据完成了全球首秀：中国慢乙肝患者功能性治愈率最高可达61%，疗效与安全性趋势与全球数据一致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083868286383.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609083868286383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK.UK","BK4200","GSKH","BK4585","GSK","BK4561","LU1829250122.USD","BK4588","BK4007","ASO","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665535012","title":"功能性治癒率最高61%！乙肝新藥中國數據出爐 但7500萬患者的「治癒夢」仍有門檻","url":"https://stock-news.laohu8.com/highlight/detail?id=2665535012","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665535012?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 12:14","pubTimestamp":1788581677,"startTime":"0","endTime":"0","summary":"【功能性治愈率最高61%！乙肝新药中国数据出炉 但7500万患者的“治愈梦”仍有门槛】8月31日—9月5日，在新加坡召开的亚洲肝病学峰会（AHS）暨HBV（乙型肝炎病毒）治愈科学会议上，反义寡核苷酸（ASO）药物Bepirovirsen全球Ⅲ期研究（B-Well研究）的中国人群数据完成了全球首秀：中国慢乙肝患者功能性治愈率最高可达61%，疗效与安全性趋势与全球数据一致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609053865995314.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609053865995314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4017","BK4007","LU1223083913.SGD","BK4532","XME","SGDM","ALT","SIL","BK4599","LU1878469433.USD","BK4200","GSK.UK","CHB","GSK","GSKH","BK4588","LU1829250122.USD","LU1223082196.USD","BK4139","GDXJ","CDE","BK4561","LU1223082519.USD","ASO","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664960827","title":"總額可達12.95億美元！和黃全球首創偶聯藥物出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2664960827","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664960827?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:03","pubTimestamp":1788422625,"startTime":"0","endTime":"0","summary":"9月3日，和黄医药（00013.HK）宣布旗下子公司和记黄埔与葛兰素史克（GSK）附属公司达成独家开发及许可协议，授予后者除中国大陆、香港、澳门和台湾以外的全球范围内开发和商业化HMPL-A830的权利。临床开发将首先聚焦于结直肠癌、胰腺癌和肺癌适应症。协议包括1.1亿美元的首付款以及潜在的开发、注册和商业化里程碑付款，总额可达12.95亿美元，外加基于净销售额的特许权使用费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033864044420.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609033864044420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK","BK1191","GSK.UK","LU1829250122.USD","BK1587","BK4532","BK4588","BK4585","BK4007","00013","BK1588","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124565155","title":"和黃醫藥午後飆升逾16%，與葛蘭素史克達成最高12.95億美元腫瘤藥授權合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1124565155","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124565155?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 15:56","pubTimestamp":1788422188,"startTime":"0","endTime":"0","summary":"$和黄医药(00013)$周四午后股价大幅走高，一度升逾16%，势创2022年11月以来最大单日升幅。消息面上，和黄医药周四宣布，旗下公司与$葛兰素史克(GSK)$附属公司签署独家开发及许可协议，双方将合作开发及商业化在研肿瘤药物HMPL-A830。根据协议，和黄医药将获得1.1亿美元首付款，并有权获得最高12.95亿美元的开发、监管及商业化里程碑付款，以及产品上市后的净销售额特许权使用费。受大额授权合作消息刺激，和黄医药午后获资金明显追捧，股价升幅迅速扩大。","market":"hk","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSKH","00013","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663282078","title":"藥聞 | 英硅智能上市後首份半年報扭虧 創新藥研發加速擁抱AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2663282078","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663282078?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 15:35","pubTimestamp":1788161758,"startTime":"0","endTime":"0","summary":"新华财经上海8月31日电（记者杜康）作为AI制药领域代表性企业之一，英硅智能（03696.HK）日前发布2026年度中期业绩报告。上半年，公司实现总营收1.063亿美元，同比增长287.2%；净利润3554万美元，经调整净利润5123万美元，经营活动现金流转正。这是英硅智能上市后发布的首份半年报，公司也由此前的亏损转为盈利。从收入结构看，药物研发与管线开发仍是主要来源。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860072952.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860072952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["APXH","GSKH","BK4585","AGIX","QTOC","WRND","PBE","XLVI","AIPO","BBP","IBB","ARTY","BK4588","BIOY","GDOC","CHAT","VTHR","SBIO","LFSC","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044177","title":"聯環藥業上半年扭虧為盈 集採續採與創新藥研發協同推進","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044177","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663044177?lang=zh_tw&edition=fundamental","pubTime":"2026-08-30 21:12","pubTimestamp":1788095520,"startTime":"0","endTime":"0","summary":"业绩实现扭亏为盈经营基本面持续改善今年上半年，联环药业经营业绩实现明显改善。对此，联环药业正持续推进相关工作。值得注意的是，联环药业已经开始围绕创新药商业化进行营销体系布局。除LH-1801外，联环药业产品注册申报也取得阶段性进展。从核心产品稳定销售，到集采品种持续放量，再到创新药研发向上市申报环节推进，联环药业正在逐步形成多层次的业务增长支撑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBB","600513","LFSC","BBP","BK0239","GSKH","BIOY","GDOC","WRND","XLVI","PBE","BK4588","BK4585","SBIO","APXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662606708","title":"能夠治癒乙肝的新藥來了？專家：距離攻克乙肝仍有差距，但臨床多了一件新武器","url":"https://stock-news.laohu8.com/highlight/detail?id=2662606708","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662606708?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 19:15","pubTimestamp":1787915749,"startTime":"0","endTime":"0","summary":"乙肝治疗领域迎来历史性突破。近日，葛兰素史克（GSK）宣布，其反义寡核苷酸（ASO）药物贝普若韦生（Bepirovirsen）已在日本获批上市，用于治疗既往接受过至少6个月核苷（酸）类似物治疗且符合预先设定的病毒学指标的成年慢性乙型肝炎（CHB）病毒感染患者，以达到功能性治愈的目的。据悉，这是Bepirovirsen在全球范围内的首次获批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608283858475454.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608283858475454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SIL","LU1829250122.USD","BK4007","LU1223082519.USD","BK4200","BK4588","SGDM","CAM","GSKH","ASO","GDXJ","GSK","GSK.UK","LU1223083913.SGD","XME","LU1223082196.USD","BK4017","BK4585","IBBQ","BK4532","CDE","BK4561","CHB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662081157","title":"葛蘭素史克(GSK)擬發行至少20億歐元債券，以償還併購融資貸款。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662081157","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662081157?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 18:00","pubTimestamp":1787824828,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["NBIE","ARB","TFNS","PEX","GSKH","RSPF","MNA","BK4007","FXE","GSK.UK","LBO","BNDW","MRGR","BUYO","LQPE","BK4585","LU1829250122.USD","BK4532","GSK","FYLG","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662752987","title":"博濟醫藥2026年半年報：創新藥研發需求復甦，在手訂單充足，經營現金流明顯下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662752987","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662752987?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 14:57","pubTimestamp":1787813849,"startTime":"0","endTime":"0","summary":"然而，需警惕新药研发政策变化、项目执行延期及市场竞争加剧带来的风险，同时关注经营现金流与净利润背离的情况。后续需重点关注公司在手订单转化进度、临床前及临床研究服务的毛利率变化趋势，以及经营现金流的改善情况。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787797151251328663","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BBP","GSKH","IBB","LFSC","PBE","BK0216","SPHQ","GDOC","BIOY","XLVI","BK4585","APXH","300404","BK4588","WRND","SBIO","159399"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660493380","title":"GSK：NUCALA獲加拿大藥品管理局積極報銷推薦，用於成人慢性阻塞性肺疾病治療。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660493380","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660493380?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 22:23","pubTimestamp":1787062997,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GSKH","BK4585","LU1829250122.USD","GSK","GSK.UK","BK4532","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660456776","title":"中外製藥與葛蘭素史克簽署抗登革熱病毒抗體「AID351」獨家許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2660456776","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660456776?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 10:49","pubTimestamp":1787021377,"startTime":"0","endTime":"0","summary":"【中外制药与葛兰素史克签署抗登革热病毒抗体“AID351”独家许可协议】据中外制药官网消息，8月18日，中外制药宣布已与葛兰素史克签署独家许可协议，葛兰素史克将获得抗登革热病毒抗体药物“AID351”的全球独家开发、生产和商业化权利，并负责该药物的临床开发及生产。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608183844335660.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608183844335660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK1574","GSKH","BK4585","LU1829250122.USD","BK4532","GSK.UK","BK4007","GSK","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660456160","title":"中外製藥與葛蘭素史克達成協議，共同推進登革熱抗體藥物開發","url":"https://stock-news.laohu8.com/highlight/detail?id=2660456160","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660456160?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 10:38","pubTimestamp":1787020681,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","BK4588","GSK","BK4532","GSKH","BK4007","GSK.UK","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659504119","title":"中國銀河證券：實驗動物為創新藥研發剛需 小鼠+猴雙主線高景氣","url":"https://stock-news.laohu8.com/highlight/detail?id=2659504119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659504119?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 15:07","pubTimestamp":1786691225,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，实验动物为创新药研发刚需，行业壁垒深厚，两大细分赛道具备中长期成长逻辑：人源化小鼠赛道成长确定性更强、周期波动平缓;实验猴赛道供给约束强，短期价格上行带来显著业绩弹性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601881","BK0188","BBP","WRND","BK4585","161027","PBE","BK4588","APXH","06881","LFSC","BK1147","GSKH","XLVI","SBIO","BK0276","IBB","BIOY","BK1564","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659945158","title":"葛蘭素史克：董事會批准根據公司淨資產，按資產市場價值分配公司合併後股本。","url":"https://stock-news.laohu8.com/highlight/detail?id=2659945158","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659945158?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 17:58","pubTimestamp":1786615104,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","BK4585","GSK.UK","GSK","LU1829250122.USD","GSKH","BK4588","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903675","title":"百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務 不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903675","media":"央广财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658903675?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541220,"startTime":"0","endTime":"0","summary":"8月12日，百花医药（维权）（600721.SH）发布公告称，公司股票连续10个交易日内日收盘价格涨幅偏离值累计超过100%，根据上交所的有关规定，属于股票交易严重异常波动情形。公司是以小分子化学仿制药研发为主的CRO企业，不涉及创新药研发。公司2026年第一季度实现营业收入6718.29万元，同比下降30.68%，归属于上市公司股东的净利润664.27万元，同比下降67.94%。目前公司主营业务未发生重大变化，市场环境、行业政策没有发生重大调整，股价短期内连续上涨，涨幅与公司经营情况严重偏离。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-12/doc-ininamih5206238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PBE","IBB","BIOY","SBIO","BK0102","BK4588","LFSC","BK4585","BK0216","XLVI","WRND","600721","APXH","GSKH","BBP","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658692990","title":"百花醫藥(600721.SH)：不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658692990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658692990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","GDOC","LFSC","PBE","WRND","IBB","BBP","SBIO","APXH","BK4585","BIOY","GSKH","XLVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658667990","title":"百花醫藥(600721.SH)：不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658667990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658667990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百花医药(600721.SH)发布股票交易风险提示公告称，公司是以小分子化学仿制药研发为主的CRO企业，主营业务是为客户提供小分子化仿药为主的药物研发注册“一站式”全流程服务，主要研发项目多来自于客户委托加部分的公司自主立项，不涉及创新药研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PBE","BIOY","BK0102","BK4585","LFSC","WRND","GDOC","BBP","BK4588","SBIO","XLVI","IBB","GSKH","APXH","600721","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658962968","title":"東方證券：AI重構創新藥研發底座 國內相關產業鏈公司亦有望受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2658962968","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658962968?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 14:06","pubTimestamp":1786428403,"startTime":"0","endTime":"0","summary":"东方证券主要观点如下：技术颠覆成本，AI重构制药“快与省”是中国创新药崛起的底层逻辑，根基是人才红利和成本优势。专家与AI协同，将真正提升新药研发的成功率并缩短周期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AGIX","GSKH","PBE","XLVI","03958","BK0276","SBIO","AIPO","BK1564","GDOC","BK0188","QTOC","BIOY","BK0183","BK4585","600958","LFSC","BK0012","BBP","WRND","ARTY","APXH","CHAT","IBB","BK1147","VTHR","BK4588","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":96,"code":"91000000","status":"200"}]}}